Compare · DXCM vs PLSE
DXCM vs PLSE
Side-by-side comparison of DexCom Inc. (DXCM) and Pulse Biosciences Inc (PLSE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and PLSE operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 16.0x PLSE ($1.75B).
- DXCM has been more active in the news (26 items in the past 4 weeks vs 2 for PLSE).
- DXCM has more recent analyst coverage (25 ratings vs 6 for PLSE).
- Company
- DexCom Inc.
- Pulse Biosciences Inc
- Price
- $72.84+0.38%
- $25.38-5.70%
- Market cap
- $28.11B
- $1.75B
- 1M return
- +20.73%
- -
- 1Y return
- -14.94%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2016
- News (4w)
- 26
- 2
- Recent ratings
- 25
- 6
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue primarily for dermatology applications by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest PLSE
- Canaccord Genuity initiated coverage on Pulse Biosciences with a new price target
- Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
- Amendment: Director Duggan Robert W bought $12,999,988 worth of shares (660,233 units at $19.69), increasing direct ownership by 1% to 48,370,047 units (SEC Form 4)
- SEC Form 10-Q filed by Pulse Biosciences Inc
- Amendment: SEC Form SCHEDULE 13D/A filed by Pulse Biosciences Inc
- ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million
- Amendment: Chief Executive Officer Laviolette Paul A bought $295,350 worth of shares (15,000 units at $19.69), increasing direct ownership by 1,773% to 15,846 units (SEC Form 4)
- Chief Executive Officer Laviolette Paul A bought $295,350 worth of shares (15,000 units at $19.69) (SEC Form 4)
- Director Duggan Robert W bought $12,999,988 worth of shares (660,233 units at $19.69), increasing direct ownership by 1% to 48,211,433 units (SEC Form 4)
- SEC Form DEF 14A filed by Pulse Biosciences Inc